Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (131 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerbreastpatientkidney diseaseside effects
  Phrases that lowered it: generalanesthesiaallergybetween 18female
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 30 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Phase: 2/3 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 76.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Blinding: double (raises risk) · Design
• Sponsor's past trials: 42 (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dexmedetomidine,Ketamine and Their Combination to Bupivicaine on Thoracic Epidural Analgesia NCT03063671 · started 2017 · scored riskier than 8% of active trials completed
• Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery NCT04275661 · started 2020 · scored riskier than 8% of active trials completed
• Comparing the Perioperative Analgesic Effect of Two Different Volumes of Local Anesthetic Solution in Erector Spinae Plane Block in Patients Undergoing Modified Radical Mastectomy NCT05813158 · started 2022 · scored riskier than 4% of active trials completed
• Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery NCT02462681 · started 2015 · scored riskier than 8% of active trials completed
• Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC) NCT03152929 · started 2017 · scored riskier than 76% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.